Journal Mobile Options
Table of Contents
Vol. 39, No. 1, 1999
Issue release date: January 1999
Neuropsychobiology 1999;39:18–24

Antidepressants Augment Natural Killer Cell Activity: In vivo and in vitro

Frank M.G. · Hendricks S.E. · Johnson D.R. · Wieseler J.L. · Burke W.J.
aDepartment of Pathology and Microbiology, bDepartment of Psychiatry, and cEppley Institute for Research on Cancer and Related Diseases, University of Nebraska Medical Center, Omaha, Nebr., and dDepartment of Psychology, University of Nebraska at Omaha, Omaha, Nebr., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Depressed mood has been associated with reduced natural killer cell activity (NKCA). Further, amelioration of depressive symptoms by pharmacotherapy has resulted in augmented NKCA. Serotonin, an indoleamine implicated in the pathophysiology of affective disorders, enhances NKCA in vitro and lymphocytes possess serotonin transporters and receptors. The present study evaluated NKCA in depressed outpatients before and during treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Prozac®). Further, the SSRIs, fluoxetine and paroxetine (Paxil®), were also incubated in vitro with lymphoid cells to evaluate possible direct effects of SSRIs on NKCA. Depressed outpatients were administered fluoxetine (20 mg/day) for 4 weeks. NKCA and severity of depression were evaluated at weeks 0, 1, 2, and 4. Serum concentrations of fluoxetine and norfluoxetine were obtained as well. Mononuclear cells obtained from nonpatient volunteers were incubated with pharmacologic concentrations of fluoxetine or paroxetine and NKCA measured with a standard chromium release assay. Fluoxetine treatment resulted in decreased symptoms of depression and increased serum concentrations of fluoxetine and norfluoxetine. Further, fluoxetine treatment was associated with augmented NKCA in a subgroup of depressed outpatients exhibiting low NKCA at baseline. Fluoxetine had no effect on NKCA in depressed individuals exhibiting high NKCA at baseline. Incubation of mononuclear cells with fluoxetine and paroxetine augmented NKCA in vitro. The enhancing effects of antidepressants on NKCA in vivo and in vitro indicate a possible direct drug interaction with lymphoid cells during pharmacotherapy, suggesting that pharmacologic treatment of depression may result in enhanced immune competence as indexed by enhanced NKCA and that NKCA could be pharmacologically augmented with antidepressants in individuals with compromised immune function.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Stein M, Miller AH, Trestman RL: Depression, the immune system, and health and illness. Arch Gen Psychiatry 1991;48:171–177.
  2. Zorrilla EP, McKay JR, Luborsky L, Schmidt K: Relation of stressors and depressive symptoms to clinical progression of viral illness. Am J Psychiatry 1996;153:626–635.
  3. Glassman AH, Shapiro PA: Depression and the course of coronary artery disease. Am J Psychiatry 1998;155:4–11.
  4. Urch A, Muller Ch, Aschauer H, Resch F, Zielinski CC: Lytic effector cell function in schizophrenia and depression. J Neuroimmunol 1988;18:291–301.
  5. Nerozzi D, Santoni A, Bersani G, Magnani A, Bressan A, Pasini A, Antonozzi I, Frajese G: Reduced natural killer cell activity in major depression: neuroendocrine implications. Psychoneuroendocrinology 1989;14:295–301.
  6. Irwin M; Smith TL, Gillin JC: Low natural killer cytotoxicity in major depression. Life Sci 1987;41:2127–2133.
  7. Kronfol Z, Nair M, Goodson J, Goel K, Haskett R, Schwartz S: Natural killer cell activity in depressive illness: Preliminary report. Biol Psychiatry 1989;26:753–756.
  8. Irwin M, Patterson T, Smith TL, Caldwell C, Brown SA, Gillin JC, Grant I: Reduction of immune function in life stress and depression. Biol Psychiatry 1990;27:22–30.
  9. Irwin M, Brown M, Patterson T, Hauger R, Mascovich A, Grant I: Neuropeptide Y and natural killer cell activity: Findings in depression and Alzheimer caregiver stress. FASEB J 1991;5:3100–3107.
  10. Caldwell CL, Irwin M, Lohr J: Reduced natural killer cell cytotoxicity in depression but not in schizophrenia. Biol Psychiatry 1991;30:1131–1138.
  11. Kronfol Z, Starkman M, Nair M: Natural killer cell activity in major depression and Cushing’s syndrome. Biol Psychiatry 1991;29:43A–185A.
  12. Irwin M, Lacher U, Caldwell C: Depression and reduced natural killer cytotoxicity: A longitudinal study of depressed patients and control subjects. Psychol Med 1992;22:1045–1050.
  13. Maes M, Stevens W, Peeters D, DeClerck L, Scharpe S, Bridts C, Schotte C, Cosyns P: A study on the blunted natural killer cell activity in severely depressed patients. Life Sci 1992;50:505–513.
  14. Evans DL, Folds JD, Petitto JM, Golden RN, Pedersen CA, Corrigan M, Gilmore JH, Silva SG, Quade D, Ozer H: Circulating natural killer cell phenotypes in men and women with major depression. Arch Gen Psychiatry 1992;49:388–395.
  15. Zisook S, Shuchter SR, Irwin M, Darko DF, Sledge P, Resovsky K: Bereavement, depression, and immune function. Psychiatry Res 1994;52:1–10.
  16. Kook AI, Mizruchin A, Odnopozov N, Gershon H, Segev Y: Depression and immunity: the biochemical interrelationship between the central nervous system and immune system. Biol Psychiatry 1995;37:817–819.
  17. Herberman RB, Djeu JY, Kay HD, Ortaldo JR, Riccardi C, Bonnard GD, Holden HT, Fagnani R, Santoni A, Puccetti P: Natural killer cells: Characteristics and regulation of activity. Immunol Rev 1979;44:43–70.

    External Resources

  18. Herberman RB, Ortaldo JR: Natural killer cells: Their role in defenses against disease. Science 1981;214:24–30.
  19. Levy EM, Borrelli DJ, Mirin SM, Salt P, Knapp PH, Pierce C, Fox BH, Black PH: Biological measures and cellular immunological function in depressed psychiatric inpatients. Psychiatry Res 1991;36:157–167.
  20. Miller AH, Asnis GM, Lackner C, Halbreich U, Norin AJ: Depression, natural killer cell activity, and cortisol secretion. Biol Psychiatry 1991;29:878–886.
  21. Schliefer SJ, Keller SE, Bond RN, Cohen J, Stein M: Major depressive disorder and immunity. Arch Gen Psychiatry 1989;46:81–87.

    External Resources

  22. Levy SM, Herberman RB, Simons A, Whiteside T, Lee J, McDonald R, Beadle M: Persistenly low natural killer cell activity in normal adults: immunological, hormonal and mood correlates. Nat Immun Cell Growth Regul 1989;8:173–186.
  23. Pariante CM, Miller AH: Natural killer cell activity in major depression: A prospective study of the in vivo effects of desmethylimipramine treatment. Eur Neuropsychopharmacol 1995;suppl:83–88.
  24. Hickie I, Silove D, Hickie C, Wakefield D, Lloyd A: Is there immune dysfunction in depressive disorders? Psychol Med 1990;20:755–761.
  25. Gold PW, Goodwin FK, Chrousos GP: Clinical and biochemical manifestations of depression. N Engl J Med 1988;319:348–420.
  26. Barden N, Reul JM, Holsboer F: Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 1994;18:11.
  27. Balogh S, Fitzpatrick DF, Hendricks SE, Paige SR: Increases in heart rate variability with successful treatment in patients with major depressive disorder. Psychopharmacol Bull 1993;8:201–206.
  28. Faraj BA, Olkowski ZL, Jackson RT: Expression of a high-affinity serotonin transporter in human lymphocytes. Int J Immunopharmacol 1994;16:561–567.
  29. Hellstrand K, Hermodsson S: Enhancement of human natural killer cell cytotoxicity by serotonin: Role of non-T/CD16+ NK cells, accessory monocytes, and 5-HT1a receptors. Cell Immunol 1990;127:199–214.

    External Resources

  30. Spitzer RL, Williams JB, Gibbon M, First MB: Structured clinical interview for DSM-III- R-Non-Patient Edition (SCID-NP, Version 1.0). Washington, American Psychiatric Press, 1990.
  31. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
  32. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS: Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;1:51–63.
  33. Wong SH, Dellafera SS, Fernandes R: Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. J Chromatogr 1990;499:601–608.
  34. Burke WJ, Hendricks SE, McArthur-Campbell D, Jacques D, Stull T: Fluoxetine and norfluoxetine concentrations and clinical response to weekly versus daily dosing. Psychopharmacol Bull 1996;32:27–32.
  35. Shekelle RB, Raynor WJ, Ostfeld AM, Garron DC, Bieliauskas LA, Liu SC, Maliza C, Oglesby P: Psychological depression and 17-year risk of death from cancer. Psychosom Med 1981;43:117–125.

    External Resources

  36. Cohen S, Herbert TB: Health psychology: Psychological factors and physical disease from the perspective of human psychoneuroimmunology. Annu Rev Psychol 1996;47:113–142.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50